Rafael Holdings, Inc. - 8-K Filing
Rafael Holdings submits NDA for remibetadex following Phase 3 TransportNPC study results showing significant disease slowing in prespecified patient subgroup. (Items: 7.01 Regulation FD From November 9, 2026, the slide presentation (the “Presentation”) attached hereto as Exhibit 99, 9.01 Financial Statements and Exhibits)
Tickers: $RFL